NEW YORK (GenomeWeb News) – Epigenomics today said that the US Food and Drug Administration has accepted its premarket approval application for its colorectal cancer test and has granted the application priority review status.

The Berlin, Germany-based firm filed the PMA for its Epi proColon test in December, after successfully completing a head-to-head comparative study with fecal immunochemical test screening. The submission was the fourth and final module of the PMA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.